Akebia Therapeutics Inc

AKBANASDAQ NMS - GLOBAL MARKET

Health CareBiotechnology

$1.02

-0.030000 (-2.86%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $0.8800Current: $1.0252-Week High: $4.08

Key Statistics

Open

$1.04

Day High

$1.06

Day Low

$1.02

Prev. Close

$1.05

Volume

2.67M

Avg. Volume

—

Market Cap

$273.62M

P/E (TTM)

-13.23

Forward P/E

—

P/B Ratio

—

52W High

$4.08

52W Low

$0.8800

50D MA

$1.30

200D MA

$1.86

Dividend Yield

—

Beta

—

Performance

+0.0%

-25.0%

-35.0%

YTD

-34.2%

-66.3%

About

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of oral medications developed for the treatment of anemia in chronic kidney disease (CKD). These drugs work by inhibiting hypoxia-inducible factor-proline dioxygenase, which are responsible for the degradation of hypoxia-inducible factor (HIF) under normal oxygen conditions. By stabilizing HIF, these inhibitors mimic the body's natural response to hypoxia, leading to increased endogenous erythropoietin production and improved iron metabolism. HIF-PHIs have shown efficacy in correcting and maintaining hemoglobin levels in both dialysis-dependent and non-dialysis-dependent CKD patients, offering an alternative to traditional erythropoiesis-stimulating agents (ESAs).

akebia.com/